Warner Chilcott reports higher Q3 net income, updates guidance for 2012

Warner Chilcott, a specialty pharmaceutical company, has reported that net income for the third quarter ended September 30, 2012 was $113 million, or $0.45 per diluted share, compared to $33 million, or $0.13 per diluted share, for the same quarter ended September 30, 2011. For 2012, the company expects GAAP net income to be in a range of $307 million to $332 million, compared to prior guidance of $265 million to 290 million.

Total revenues for the third quarter of 2012 were $606 million, compared to $655 million for the same quarter of 2011.

Net income for the nine months ended September 30, 2012 was $279 million, or $1.11 per diluted share, compared to $81 million, or $0.32 per diluted share, for the same period ended September 30, 2011.

Total revenues for the nine months ended September 30, 2012 were $1.93 billion, compared to $2.08 billion for the same period ended September 30, 2011.

Total revenue for 2012 is expected to be in a range of $2.4 billion to $2.5 billion.